TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20068365
Drug: alpha-interferon 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-interferon 0.5 million IU b.i.d., thalidomide (100 mg b.i.d. reduced to 100 mg daily), or celecoxib (400 mg daily reduced to 200 mg)
Study: 20068365
Drug: two-drug combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: two-drug combinations of alpha-interferon, thalidomide or celecoxib
Study: 11281338
Drug: Trandolapril 2
Normalized name: trandolapril 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril 2 mg and verapamil 180 mg
Study: 11281338
Drug: Trandolapril 2
Normalized name: trandolapril 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril 2 mg and amlodipine 5 mg
Study: 9004107
Drug: Trandolapril 2
Normalized name: trandolapril 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril 2 mg
Study: 9400948
Drug: G-CSF given
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF given daily on days 7-17 to all patients
Study: 24931756
Drug: Parenteral Dipeptiven(®)
Normalized name: palmitoyl dipeptide-7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral Dipeptiven(®) supplementation of 0.5 g/kg/day
Study: 23609487
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy‐based self‐help program delivered by the Internet with e‐mail guidance
Study: 19176222
Drug: Schema-focused therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schema-focused therapy (SFT) combined with treatment-as-usual (TAU)
Study: 28066274
Drug: Treatment-as-usual (TAU)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (TAU) alone
Study: 17522560
Drug: Oral haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral haloperidol
Study: 15474895
Drug: D-cycloserine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-cycloserine (50 mg p.o. QD)
Study: 12126875
Drug: Buspirone 30
Normalized name: busPIRone 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone 30 mg administered orally
Study: 9576366
Drug: Intraperitoneal calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal calcitriol (5.4 ± 1.2 microg/week, maximum 6.6 ± 1.5 microg/week) administered twice per week before bedtime.
Study: 2651014
Drug: 4.5 mg
Normalized name: phenol 14.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 mg ergoloid mesylates per day
Study: 144507
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg D-penicillamine (DP)
Study: 144507
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg D-penicillamine (DP)
Study: 31422458
Drug: IV PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV PCA oxycodone
Study: 28860712
Drug: Oral oxycodone
Normalized name: oxycodone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oxycodone
Study: 25432952
Drug: 125 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 µg peginterferon beta‐1a every 2 weeks
Study: 25432952
Drug: 125 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 µg peginterferon beta‐1a every 4 weeks
Study: 21288774
Drug: Protease inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor and switch to second-line at 1000 copies per mL (PI-low)
Study: 21288774
Drug: Protease inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor and switch at 30,000 copies per mL (PI-higher)
Study: 21288774
Drug: NNRTI and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNRTI and switch at 1000 copies per mL (NNRTI-low)
Study: 21288774
Drug: NNRTI and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNRTI and switch at 30,000 copies per mL (NNRTI-higher)
Study: 21288774
Drug: Switching at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching at low threshold (1000 copies per mL)
Study: 21288774
Drug: Switching at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching at higher threshold (30,000 copies per mL)
Study: 18440181
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment strategies
Study: 16081106
Drug: CBZ monotherapy
Normalized name: CBZ
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CBZ monotherapy
Study: 10561191
Drug: G-CSF +
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF + EPO
Study: 10831021
Drug: Alprazolam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (1 mg, administered orally)
Study: 8922889
Drug: Half-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Half-dose aprotinin during surgery
Study: 15587753
Drug: Cefcapene pivoxil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefcapene pivoxil (CFPN-PI; 450 mg/day)
Study: 15587753
Drug: Cefteram pivoxil
Normalized name: cefteram pivoxil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefteram pivoxil (CFTM-PI; 600 mg/day)
Study: 3396372
Drug: Kinetic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinetic treatment table
Study: 29533115
Drug: Cholecalciferol 2,000
Normalized name: CHOLECALCIFEROL 2,000UNIT TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 2,000 IU daily with standard chemotherapy
Study: 23423452
Drug: Etiquette-based medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etiquette-based medicine (EtBM) behaviors performed by hospitalists
Study: 23423452
Drug: Etiquette-based medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etiquette-based medicine scores
Study: 21219197
Drug: Oral amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amino acid supplementation (4 g thrice a day) for 3 months
Study: 11212974
Drug: Lisinopril (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (10-20 mg)
Study: 11117374
Drug: Enalapril (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10-20 mg)
Study: 1580094
Drug: Hydroxyethylrutosides 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethylrutosides 500 mg (normal volunteers)
Study: 1580094
Drug: Hydroxyethylrutosides 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethylrutosides 1000 mg (patients with venous hypertension and diabetic microangiopathy)
Study: 23332288
Drug: Pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2)
Study: 22434360
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus cisplatin (75 mg/m2)
Study: 15976248
Drug: Gargling with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gargling with sodium azulene sulfonate (Azunol) 4 mg diluted with 100 mL tap water (40 microg/mL)
Study: 11466189
Drug: 150 microg
Normalized name: Norgestrel 150 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 microg fluticasone twice daily (group F)
Study: 2604508
Drug: Prophylactic doses
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic doses of vitamin D during the first 3 months of LT4 treatment
Study: 2604508
Drug: No vitamin
Normalized name: Vitamin B12 NOS
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No vitamin D during the first 3 months of LT4 treatment
Study: 28385154
Drug: Second dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second dose of PZQ
Study: 24518967
Drug: Celecoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (400 mg/day for 24 weeks)
Study: 19754867
Drug: 0.1% tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% tacrolimus ointment (twice weekly as maintenance treatment)
Study: 19754867
Drug: Emollient vehicle
Normalized name: SUSPENDING VEHICLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emollient vehicle (standard treatment)
Study: 19754867
Drug: 0.1% tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% tacrolimus ointment (twice daily during OLP)
Study: 7988813
Drug: Cefotaxime 2
Normalized name: cefotaxime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 2 g intravenous infusion 15 minutes before ERCP
Study: 2686711
Drug: Dilevalol twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilevalol twice daily (N = 55)
Study: 2686711
Drug: Dilevalol once
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dilevalol once daily (N = 40)
Study: 20196640
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (HT) with tamoxifen
Study: 25858103
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (HT) plus chemotherapy (CT)
Study: 19878781
Drug: Nonsteroidal cream
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal cream (Promiseb Topical Cream)
Study: 19878781
Drug: Desonide cream
Normalized name: Desonide Cream
DrugBank: Desonide sodium phosphate (DB15835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desonide cream 0.05%
Study: 17514706
Drug: Routine information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine information preparation (Control)
Study: 8733329
Drug: Amoxycillin/clavulanate bid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin/clavulanate bid at a dose of 25/3.6mg/kg/day for 7 days
Study: 8733329
Drug: Amoxycillin/clavulanate tid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin/clavulanate tid at a dose of 20/5mg/kg/day for 7 days
Study: 2253536
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg orally four times a day
Study: 7001486
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg protacine, 3-times daily, orally, for 10 days
Study: 7001486
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg indomethacin, 3-times daily, orally, for 10 days
Study: 7001486
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg protacine, 3-times daily, orally, for 18 days
Study: 7001486
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg oxyphenbutazone, 3-times daily, orally, for 18 days
Study: 22453003
Drug: Acarbose (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (150 or 300 mg/day)
Study: 19094763
Drug: Triptorelin 11.25
Normalized name: triptorelin 11.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin 11.25 mg (one injection)
Study: 19094763
Drug: Triptorelin 3.75
Normalized name: triptorelin 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin 3.75 mg (three injections at 28-day intervals)
Study: 15961681
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion (0.16 micromol/kg min)
Study: 12626215
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate 40 mg daily plus estradiol valerate 2 mg daily
Study: 9589363
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg oltipraz weekly
Study: 9589363
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg oltipraz daily
Study: 8927288
Drug: Alendronate 20
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate 20 mg/day for six months
Study: 6507769
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (sal)
Study: 31213040
Drug: 5 mL/h
Normalized name: ropivacaine HCl/PF 0.2 % 5 mL/hour 500 mL INJECTION ELASTOMERIC PUMP, FIXED RATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL/h BEI + 10 mL/h PIEB
Study: 31213040
Drug: 5 mL/h
Normalized name: ropivacaine HCl/PF 0.2 % 5 mL/hour 500 mL INJECTION ELASTOMERIC PUMP, FIXED RATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL/h BEI of levobupivacaine 0.125% plus fentanyl 1.45 µg/mL (standard group)
Study: 30423955
Drug: Flavonoid supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavonoid supplementation (329 mg/day) with 45-minute walking (62.2 +/- 0.9% VO2max)
Study: 30423955
Drug: Runners ingested
Approvals — FDA: no, EMA: no, PMDA: no
Description: Runners ingested a double flavonoid dose (658 mg/day) and ran for 2.5 h (69.2 +/- 1.2% VO2max)
Study: 26164110
Drug: Cognitive Therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Therapy (CT) plus pharmacotherapy
Study: 20335369
Drug: CERA 6.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: CERA 6.3 μg/kg
Study: 20335369
Drug: CERA 9
Normalized name: CERA
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CERA 9 μg/kg
Study: 20335369
Drug: CERA 12
Normalized name: MIRCERA 120mcg/0.3mL Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: CERA 12 μg/kg
Study: 20335369
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa (6.75 μg/kg every 3 weeks or 2.25 μg/kg weekly)
Study: 17926466
Drug: Leflunomide (LF)
Normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leflunomide (LF) 100 mg/day for 3 days then 20 mg/day for 6 months
Study: 11943259
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 500 mg plus Vitamin E 400 IU, each twice daily (n=19)
Study: 9794352
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 16 mg once daily for 8 weeks
Study: 9794352
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 32 mg once daily for 8 weeks
Study: 110184
Drug: RIF 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIF 600 mg
Study: 110184
Drug: RIF 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIF 750 mg
Study: 110184
Drug: RIF 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIF 450 mg
Study: 110184
Drug: RIF-EMB therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIF-EMB therapy (300 mg INH and 15 mg EMB per kg)
Study: 110184
Drug: 12 months
Normalized name: Elecare HMO 0-12 Months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 months of chemotherapy after sputum conversion
Study: 110184
Drug: RIF-INH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIF-INH therapy
Study: 27628062
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept (2.0 mg) administered as three monthly doses followed by injections every 2 months
Study: 25827058
Drug: Pioglitazone (PIO,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (PIO, 15 mg for 6 weeks, then 30 mg daily)
Study: 24246211
Drug: Doxazosin 4
Normalized name: doxazosin 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 4 mg daily plus celecoxib 200 mg daily (study group)
Study: 24246211
Drug: Doxazosin 4
Normalized name: doxazosin 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 4 mg daily alone (control group)
Study: 21575919
Drug: Trandolapril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril (4 mg, n=10)
Study: 21575919
Drug: Verapamil (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (240 mg, n=10)
Study: 21575919
Drug: Trandolapril (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril (2 mg) + Verapamil (180 mg, n=10)
Study: 19627355
Drug: Tin-containing fluoride
Normalized name: stannous fluoride Oral Gel [Gel-Tin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tin-containing fluoride solutions (400 ppm Sn2+, 1,500 ppm F-, pH 4.5)
Study: 19627355
Drug: Tin-containing fluoride
Normalized name: stannous fluoride Oral Gel [Gel-Tin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tin-containing fluoride solutions (1,400 ppm Sn2+, 1,500 ppm F-, pH 4.5)
Study: 19627355
Drug: Tin-containing fluoride
Normalized name: stannous fluoride Oral Gel [Gel-Tin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tin-containing fluoride solutions (2,100 ppm Sn2+, 1,500 ppm F-, pH 4.5)
Study: 19660515
Drug: Negative control
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative control group (no treatment)
Study: 19627355
Drug: Test solutions
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test solutions without demineralization (twice daily)
Study: 16417535
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) at doses up to 2000 mg/day
Study: 8193987
Drug: Intravenous propafenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propafenone 1.5 mg/kg infused over 5 mins
Study: 7936333
Drug: Intravenous propafenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propafenone
Study: 2822924
Drug: Intraarticular deferoxamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular deferoxamine 100 mg
Study: 29913174
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (60 mg, initiated at 13-25 weeks' gestation)
Study: 23294659
Drug: Resonant breathing
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resonant breathing biofeedback training (5 weekly sessions)
Study: 16005384
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg of D‐amphetamine
Study: 12404670
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitors (paroxetine and citalopram)
Study: 2158260
Drug: ICI 204,219
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 204,219 (40 mg oral dose)
Study: 335584
Drug: PUFA preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUFA preparation
Study: 26223506
Drug: Topical agent
Normalized name: topical agent combination no.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical agent A (20% aluminum chloride hexahydrate)
Study: 26223506
Drug: Topical agent
Normalized name: topical agent combination no.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical agent B (1% aluminum acetate)
Study: 23223947
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ropivacaine and 2 μg sufentanil in 30 mL 0.9% saline (Group B)
Study: 23223947
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ropivacaine in 30 mL 0.9% saline (Group C)
Study: 23223947
Drug: 2 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 μg sufentanil in 30 mL 0.9% saline (Group D)
Study: 23223947
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL of 0.9% saline (Group A)
Study: 18180761
Drug: Brief intensive
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief intensive cognitive-behavioral therapy (CBT)
Study: 19335435
Drug: Normal controls
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal controls (no treatment)
Study: 11693075
Drug: Pharmaceutical Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical Care (PhC)
Study: 9383924
Drug: Innovative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Innovative treatment applications and strategies to integrate research and practice
Study: 7523480
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody based kits
Study: 7523480
Drug: Monoclonal antibodies
Normalized name: Monoclonal antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibodies specific for the holohormone (anti-alpha beta)
Study: 30039790
Drug: Single quadrant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single quadrant injection technique (Group S)
Study: 30039790
Drug: Two quadrants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two quadrants injection technique (Group C)
Study: 30905173
Drug: Acupuncture (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (twice weekly for 8 weeks)
Study: 26365445
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no anti-hypertensive treatment for 12 weeks)
Study: 21175845
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) bolus abciximab
Study: 9146775
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg effervescent
Study: 9146775
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg effervescent
Study: 9146775
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg capsules
Study: 8190296
Drug: Entacapone (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entacapone (acute and chronic administration)
Study: 6138053
Drug: Oxazepam 30
Normalized name: oxazepam 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam 30 mg
Study: 28335745
Drug: Lidocaine/prilocaine (25/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine/prilocaine (25/25 mg, 10 cm2, application duration: 60 min)
Study: 23314743
Drug: LCI699 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCI699 (0.5 mg b.i.d. for 14 days, then 1 mg b.i.d. for 15 days)
Study: 23314743
Drug: Eplerenone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (50 mg b.i.d., up-titrated to 100 mg b.i.d. in 12/14 patients)
Study: 23314743
Drug: Eplerenone (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (50-100 mg b.i.d.)